创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: Unique Features of the CDX Modeling Platform

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-12 15:09
  • Views:

(Summary description)In the field of biomedicine, tumor research has always been a key area pursued by researchers. In order to more accurately and deeply study the occurrence, development and treatment process of tumors, many research institutions and enterprises are exploring and improving various experimental models. The CDX model platform launched by InnoModels Biotechnology, with its unique features, is leading the new direction of tumor research

InnoModels Biotechnology: Unique Features of the CDX Modeling Platform

(Summary description)In the field of biomedicine, tumor research has always been a key area pursued by researchers. In order to more accurately and deeply study the occurrence, development and treatment process of tumors, many research institutions and enterprises are exploring and improving various experimental models. The CDX model platform launched by InnoModels Biotechnology, with its unique features, is leading the new direction of tumor research

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-12 15:09
  • Views:
Information

In the field of biomedicine, tumor research has always been a key area pursued by researchers. In order to more accurately and deeply study the occurrence, development and treatment process of tumors, many research institutions and enterprises are exploring and improving various experimental models. The CDX model platform launched by InnoModels Biotechnology, with its unique features, is leading the new direction of tumor research.
1. Highly reproducible real tumor environment
CDX model, i.e. patient-derived xenograft model, refers to the transplantation of patient's tumor tissues into immunodeficient mice so that they can grow and develop in the new host environment. By virtue of its exquisite technology and strict operation procedures, the CDX model platform of InnoModels Biotechnology can highly reproduce the real tumor environment and ensure that the transplanted tumor tissues are highly consistent with the original tumors in terms of their biological characteristics and growth patterns.
2. Research on personalized treatment strategies
The CDX model platform allows researchers to conduct research on tumor tissues of specific patients so as to develop personalized treatment strategies for patients. By monitoring and analyzing the growth of a patient's tumor tissue in vivo, researchers can evaluate the efficacy of different drugs or treatments, and thus screen out the most suitable treatment plan for the patient.
3、Efficient drug screening and R&D
Drug screening and R&D is an important part of tumor research. By simulating the real tumor environment, InnoModels' CDX model platform can more accurately reflect the efficacy and toxicity of drugs in vivo, providing powerful support for drug screening and R&D. At the same time, the platform can also conduct in-depth research on the mechanism of drug action, providing a theoretical basis for the development of new drugs.

 


4、Powerful interdisciplinary cooperation ability
CDX modeling platform is not only suitable for basic science research, but also can be deeply integrated with clinical research, translational medicine and other fields. InnoModels' CDX model platform provides strong support for interdisciplinary collaboration, allowing researchers to study tumors from different perspectives and at different levels. This interdisciplinary research approach helps to discover new treatments and methods and promote the in-depth development of tumor research.
5. High attention to ethics and compliance
When using patient-derived tissues for research, the issues of ethics and compliance are particularly important. In the design and operation of the CDX model platform, InnoModels strictly abides by relevant ethical and regulatory requirements to ensure that patients' privacy and rights are fully protected. At the same time, the platform also focuses on animal welfare and ethical issues to minimize pain and harm to animals.
6. Summary
With its unique features such as highly restoring the real tumor environment, personalized therapeutic strategy research, efficient drug screening and development, strong interdisciplinary cooperation capabilities, and high attention to ethics and compliance, the CDX model platform of InnoModels Biotechnology has demonstrated great potential and value in the field of oncology research. With the continuous progress and improvement of the technology, it is believed that the CDX model platform will play an even more important role in future tumor research and make greater contributions to human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司